Thus, AGP represents a potential target molecule for therapeutic development in AKI or its progression to CKD, and AGP or AGP-inducing agents could be a potential therapeutic agent against AKI and its progression to CKD. This evidence concerns the gene ATP5MK and acute kidney injury.